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Introduction: Lung and gastric cancers are the first and second leading causes of death from cancer worldwide,
and are especially prevalent in Eastern Asia. Relatively few reports are available in relation to the treatment and
outcome of synchronous lung and gastric cancers, although there are increasing numbers of patients with these
cancers. Efforts to develop more effective drugs for the treatment of synchronous cancers, without serious adverse
effects, have been intensifying. Pemetrexed, a multi-targeted antifolate enzyme inhibitor, was approved by the
United States Food and Drug Administration as a first-line chemotherapy for advanced non-squamous non-small
cell lung cancer in 2007. Although clinical activity against several tumor types of adenocarcinoma, including gastric
cancer, has been demonstrated, the efficacy of pemetrexed for gastric cancer remains to be fully evaluated.
Case presentation: We report a case involving a 62-year-old Japanese woman with synchronous locally-advanced
poorly-differentiated lung adenocarcinoma and poorly-differentiated gastric adenocarcinoma, containing signet-ring
cells distinguished by immunohistochemical profiles. She had been treated with carboplatin and pemetrexed as a
first-line chemotherapy for lung cancer, and had achieved partial responses for both lung and gastric cancers.
These responses led to a favorable 12-month progression-free survival after the initiation of chemotherapy, and the
patient is still alive more than 33 months after diagnosis.
Conclusions: This case suggests a new chemotherapeutic regimen for patients with synchronous multiple primary
cancers that have an adenocarcinoma background.Introduction
The incidence of synchronous cancers has increased be-
cause of the reduced mortality resulting from improved
treatments and the development of advanced tools for
the early detection of cancerous lesions. Although gas-
tric cancer used to be ranked as the most common can-
cer, especially in Eastern Asia, recent epidemiological
studies have revealed that lung cancer is the leading
cause of death from cancer in Japan, exceeding gastric,
colorectal and breast cancer in rates of mortality [1,2].
Thus, more patients with synchronous and metachro-
nous lung and gastric cancers are now encountered.
However, few reports are available regarding treatment* Correspondence: takashisato1220@gmail.com
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reproduction in any medium, provided the orand outcome, especially in the case of synchronous
forms of these cancers. Here, we report on the case of a
patient with synchronous non-small cell lung cancer
(NSCLC) and early gastric cancer that were successfully
treated with carboplatin plus pemetrexed.Case presentation
A 62-year-old Japanese woman with a history of smok-
ing presented to a neighborhood clinic because of an
abnormal shadow in her right lower lung field seen on
a chest X-ray taken during an annual medical checkup.
A chest computed tomography (CT) scan demonstrated
a solitary lung tumor with an irregular border and a
spiculated formation in segment 10 of her right lung,
and enlarged right hilar and mediastinal lymph nodes
(LNs), suggesting primary lung carcinoma (Figure 1).d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Gastric lesion observed by gastroscopy before and
after treatment with carboplatin plus pemetrexed. (A)
Computed tomography scans before treatment showing the tumor
at a maximal diameter of 36mm with an irregular border in segment
10 of the right lung and (B) shrinking tumor judged as a partial
response after four cycles of carboplatin plus pemetrexed.
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detailed evaluation.
Our patient was fairly asymptomatic with no history of
respiratory tract infection, chronic cough or bloody
sputum; however, she did complain of epigastric pain.
Conventional laboratory data showed iron deficiency
anemia and elevated levels of carcinoembryonic antigen
(121ng/mL) and sialyl Lewis X-i antigen (90μg/mL).
Bronchofiberscopy was performed and biopsy specimens
were obtained from the primary tumor in segment 10
of her right lung. Microscopic examination of the
specimens showed adenocarcinoma without an epider-
mal growth factor receptor mutation. In addition,
gastrointestinal tract endoscopy was performed one day
after the bronchofiberscopy, and revealed a gastric
cancer located on the antral anterior wall of her stomach
(Figure 2). The biopsy specimen was positive for poorly-
differentiated adenocarcinoma cells containing signet-ring cells (Figure 3), which were confined within the
submucosal layer. Immunohistochemical tests were posi-
tive for thyroid transcription factor-1, cytokeratin (CK)7
and mucin (MUC)-1 in the lung tumor, but negative
in the gastric tumor. On the other hand, immunostain-
ing was positive for CK7, CK20, MUC5AC and caudal
type homeobox 2 expression in the gastric tumor,
but negative in the lung tumor, indicating that each
adenocarcinoma was a synchronous double cancer. Sys-
temic evaluation, including fluorine-18-fluorodeoxyglucose
positron emission tomography, showed no evidence of
accumulation other than lung and multiple mediastinal
LNs, suggesting a diagnosis of locally advanced NSCLC
(Stage IIIA) and early stage IIa + IIb primary gastric can-
cer. The tumor in her stomach was judged as being an
inappropriate case for endoscopic mucosal resection, due
to its size and poor histological differentiation.
In accordance with our patient’s request, cisplatin-
containing regimens were not considered due to a
requirement for massive hydration and hospitalization
associated with this type of therapy. For this reason,
treatment was initiated with carboplatin (area under the
curve: 5) plus pemetrexed (500mg/m2) as a first-line
chemotherapy for the locally advanced lung cancer on
the basis of the available phase III clinical trial evidence
[3]. Chemoradiotherapy was not chosen as a treatment
option because of the requirement for an extended radi-
ation field. The combination of these drugs was tolerated
without any grade 3 or 4 adverse events, determined
according to the Common Terminology Criteria for
Adverse Events (CTCAE), version 4.0. After four cycles
of chemotherapy, the primary lung lesion had been
reduced in size and judged as a partial response (PR)
using the Response Evaluation Criteria in Solid Tumors
criteria (Figure 1). Moreover, the primary gastric lesion
was macroscopically diminished (Figure 2), although a
few signet-ring cells were still found in biopsy speci-
mens. Along with this favorable outcome, our patient
received a further four cycles of maintenance monother-
apy with pemetrexed (500mg/m2) every three weeks,
resulting in stable disease status.
Four months after the last maintenance therapy,
chest CT and gastrointestinal tract endoscopy revealed
re-growth of the primary lung lesion and recurrence of
the mucosal lesion in the stomach, resulting in progres-
sive disease with a 12-month progression-free survival.
As a second-line chemotherapy, docetaxel (60mg/m2)
was initiated and achieved a PR for the lung cancer after
three cycles of treatment, although it caused grade 4
leukopenia and neutropenia according to the CTCAE
criteria, even after a 20% reduction in dose. After six
cycles of treatment, the gastric lesion was evaluated as
slowly progressive (still judged as having stable disease
status), while the lung lesion was still diminished. A total
Figure 2 Gastric lesion observed by gastroscopy before and after treatment with carboplatin plus pemetrexed. (A) Gastroscopy
revealed a slightly elevated mucosal lesion with an irregular surface in the midanterior body of the stomach that was confirmed by biopsy
as a gastric adenocarcinoma before treatment. (B) Disappearance of the mucosal lesion after four cycles of carboplatin plus pemetrexed.
(C) Chromoendoscopy with acetic acid-indigo carmine showed a mottled image with an indistinct border before treatment and (D) normal
mucosa after four cycles of carboplatin plus pemetrexed.
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disease in the case of both the lung cancer in the enlarged
mediastinal LNs and the gastric cancer in the extended
gastric mucosal lesion. Following chemotherapy with
weekly irinotecan (100mg/m2) as a third-line chemother-
apy, our patient also exhibited grade 4 leukopenia and
neutropenia. However, the treatment was successfully
administered in the case of the lung cancer, with reduced
mediastinal LNs, and was judged as a PR after four cycles
of treatment. However, there was no response to this
chemotherapy regimen in the case of the gastric cancer,
with the disease showing further progression. Our patient
is still alive 33 months after diagnosis, and further chemo-
therapy is planned including oral fluoropyrimidine S-1 as
a gastric cancer-oriented therapy.
Discussion
The incidence of synchronous cancers of the lung and
stomach has been reported as being 0.71% and 0.72% inKorean and Japanese patients, respectively [4,5]. Of these
patients, about 50% received only radiotherapy or sup-
portive care, mainly due to the advanced stage of the
lung cancer, resulting in one- and two-year survival rates
of 50% and 32.4%, respectively [5]. Pemetrexed is a
recently developed antifolate drug shown to prolong
survival time in patients with non-squamous NSCLC
and to have a favorable toxicity profile, and was tolerated
even in patients who had received it as a third- or
further-line treatment [6]. Although activity of peme-
trexed against several breast, gastric, pancreatic and
colorectal adenocarcinoma cell lines has been reported
[7], only a limited number of phase I or II studies involv-
ing chemotherapy including pemetrexed have been car-
ried out in patients with gastric cancer; response rates
ranged from 23% to 36% [8,9]. In Japan, there is only
one case report demonstrating the efficacy of carboplatin
plus pemetrexed in patients with gastric cancer [10].
Our case showed the efficacy of docetaxel or irinotecan
AB
Figure 3 Pathology of lung and gastric tumors. (A) Poorly-
differentiated papillary adenocarcinoma from segment 10 of the
right lung composed of papillary tufts containing fibrovascular cores.
Large, atypical cells with enlarged hyperchromatic nuclei were
observed (hematoxylin and eosin, original magnification × 200).
(B) Tubular adenocarcinoma from the stomach with poorly-cohesive
lesions containing signet-ring cells. Discohesive and highly atypical
tumor cells with signet-ring cells (arrows) of intracytoplasmic mucin
or eosinophilic cytoplasm can be observed (hematoxylin and eosin,
original magnification × 200).
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tric adenocarcinoma. Taken together, we may consider
that pemetrexed plus carboplatin has greater potential ef-
ficacy and lower adverse effects compared with docetaxel
or irinotecan monotherapy in the treatment of advanced
gastric cancer, even when it is poorly differentiated.
Conclusions
Findings from our case suggest a new chemotherapeutic
regimen with low adverse effects for patients with syn-
chronous multiple primary cancers with an adenocarcin-
oma background.
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